Kamada (KMDA) Stock: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$7.92
-0.07 (-0.88%)
âŧ
5d:
-4.23%
30d:
+15.12%
90d:
+6.45%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KMDA is fairly priced but lacks strong directional signals. At -2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KMDA is fairly priced but lacks strong directional signals. At -2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.95
Based on 13.2% avg growth
INTRINSIC VALUE TODAY
$9.90
20.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $7.92, which is considered fair relative to its 30-day fair value range of $7.40 to $8.42. The stock's valuation (Forward PE: 13.3) is in line with its historical norms (14.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.8% over the next few years. This pessimistic expectation contrasts with the company's recent 23.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, KMDA is showing sideways momentum. The price is currently testing key support at $7.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KMDA scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+70.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KMDA is showing sideways momentum. The price is currently testing key support at $7.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KMDA scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+70.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.40 -
$8.42
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.5% below Wall St target ($13.50)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.40 -
$8.42
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.90
Resistance Level
$8.60
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.27
Wall Street Target
$13.50
(+70.5%)
Revenue Growth (YoY)
22.7%
Earnings Growth (YoY)
23.1%
Profit Margin
11.6%
Valuation Discount vs History
-2.8% cheaper
PE vs Historical
13.3 vs 14.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.8%
(market-implied from PE analysis)
1-Year Target
$7.70
(-3%)
2-Year Target
$7.48
(-6%)
3-Year Target
$7.27
(-8%)
3-Yr Target (if PE normalizes)
(PE: 13â15)
$7.95
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 22.4%)
$22.07
(+179%)
Base:
(SPY PE: 13.3, Growth: 22.4%)
$14.52
(+83%)
Bear:
(PE: 11.3, Growth: 22.4%)
$12.34
(+56%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 21.59 | Current EPS (TTM): $0.37
Bull Case
$14.17
(+79%)
Analyst growth 61.3%, PE expands to 23.8
Base Case
$12.89
(+63%)
Market implied 61.3%, PE stable at 21.6
Bear Case
$5.43
(-31%)
Severe decline -20.0%, PE contracts to 18.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.3 to 14.5
Stabilization Target:
$8.65
(+9.2%)
PE Expansion Potential:
+9.2%
Share & Embed Analysis
Last updated: September 13, 2026 10:05 PM ET
Data refreshes hourly during market hours. Next update: 11:05 PM
Data refreshes hourly during market hours. Next update: 11:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
